Showing results (1-10 of 33) with videos related to
Sort By:
Pageof 4
Current Stem Cell Research & Therapy|January 29, 2008
Self-renewal versus differentiation in hematopoietic stem and progenitor cells: a focus on asymmetric cell divisionsBernd Giebel, Ingmar BrunsRecent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 22, 2011
High-dose therapy and autologous peripheral blood stem cell transplantation in patients with multiple myelomaRainer Haas, Ingmar Bruns, Guido Kobbe, et al.Haematologica|October 2, 2009
Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survivalAkos Czibere, Ingmar Bruns, Bärbel Junge, et al.The Journal of Experimental Medicine|June 19, 2013
PDGFRα and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansionSandra Pinho, Julie Lacombe, Maher Hanoun, et al.Blood|March 17, 2012
Norepinephrine reuptake inhibition promotes mobilization in mice: potential impact to rescue low stem cell yieldsDaniel Lucas, Ingmar Bruns, Michela Battista, et al.Nature Medicine|May 7, 2013
Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regenerationDaniel Lucas, Christoph Scheiermann, Andrew Chow, et al.Experimental Hematology|September 20, 2006
Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myelomaRoland Fenk, Nadine Hieronimus, Ulrich Steidl, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 13, 2011
The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameterMark Korthals, Nina Sehnke, Ralf Kronenwett, et al.Leukemia & Lymphoma|December 11, 2007
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myelomaRoland Fenk, Mark Michael, Fabian Zohren, et al.Leukemia & Lymphoma|June 11, 2011
Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantationRoland Fenk, Vanessa Liese, Florian Neubauer, et al.Pageof 4